Zarogoulidis Paul, Lampaki Sofia, Turner J Francis, Huang Haidong, Kakolyris Stylianos, Syrigos Konstantinos, Zarogoulidis Konstantinos
Pulmonary Department-Oncology Unit, G. Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki 57010, Greece.
Interventional Pulmonary and Critical Care Medicine, Western Regional Medical Center, Goodyear, Arizona 85338, USA.
Oncol Lett. 2014 Dec;8(6):2367-2370. doi: 10.3892/ol.2014.2608. Epub 2014 Oct 10.
Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially identified as the cellular target of rapamycin. This kinase regulates cell growth, proliferation, motility and survival, as well as the gene transcription and protein synthesis that are activated in response to hormones, growth factors and nutrients. Results from preclinical studies have indicated that factors antagonizing the mTOR pathway exert an antitumor effect on lung cancer. Furthermore, primary clinical trials of mTOR inhibitors have demonstrated that the inhibitors may be effective against lung carcinoma. The present study explores the association between mTOR and lung carcinogenesis and describes the clinical trials of mTOR inhibitors.
雷帕霉素哺乳动物靶点（mTOR）是一种蛋白丝氨酸/苏氨酸激酶，最初被鉴定为雷帕霉素的细胞靶点。该激酶调节细胞生长、增殖、运动和存活，以及响应激素、生长因子和营养物质而激活的基因转录和蛋白质合成。临床前研究结果表明，拮抗mTOR通路的因子对肺癌具有抗肿瘤作用。此外，mTOR抑制剂的初步临床试验表明，这些抑制剂可能对肺癌有效。本研究探讨了mTOR与肺癌发生之间的关联，并描述了mTOR抑制剂的临床试验。
